TRSBF Stock - 3SBio Inc.
Unlock GoAI Insights for TRSBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.11B | $7.82B | $6.86B | $6.38B | $5.59B |
| Gross Profit | $7.83B | $6.64B | $5.67B | $5.28B | $4.52B |
| Gross Margin | 86.0% | 85.0% | 82.7% | 82.7% | 81.0% |
| Operating Income | $2.73B | $2.46B | $2.07B | $1.83B | $1.46B |
| Net Income | $2.09B | $1.55B | $1.92B | $1.65B | $835.79M |
| Net Margin | 23.0% | 19.8% | 27.9% | 25.9% | 15.0% |
| EPS | $0.86 | $0.63 | $0.78 | $0.65 | $0.33 |
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
TRSBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | — | — | — | — |
Q3 2025 | Aug 29, 2025 | $0.08 | $0.08 | -0.9% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $0.06 | $0.06 | -5.7% | ✗ MISS |
Q3 2024 | Aug 22, 2024 | $0.06 | $0.06 | +1.9% | ✓ BEAT |
Q2 2024 | Jun 25, 2024 | $0.06 | $0.03 | -41.6% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.05 | $0.06 | +14.8% | ✓ BEAT |
Q1 2023 | Mar 21, 2023 | $0.05 | $0.05 | +1.3% | ✓ BEAT |
Q3 2022 | Aug 24, 2022 | $0.04 | $0.05 | +20.5% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $0.04 | $0.04 | +8.2% | ✓ BEAT |
Q3 2021 | Aug 25, 2021 | $0.05 | $0.05 | +1.5% | ✓ BEAT |
Q1 2021 | Mar 30, 2021 | $0.04 | $0.01 | -81.5% | ✗ MISS |
Q3 2020 | Aug 17, 2020 | $0.03 | $0.04 | +12.0% | ✓ BEAT |
Q1 2020 | Mar 30, 2020 | $0.04 | $0.04 | -10.4% | ✗ MISS |
Q3 2019 | Aug 21, 2019 | — | $0.02 | — | — |
Q1 2019 | Mar 20, 2019 | — | $0.04 | — | — |
Q3 2018 | Aug 20, 2018 | $0.22 | $0.03 | -87.2% | ✗ MISS |
Q1 2018 | Mar 26, 2018 | — | $0.03 | — | — |
Q3 2017 | Aug 28, 2017 | — | $0.02 | — | — |
Q1 2017 | Mar 17, 2017 | — | $0.02 | — | — |
Q3 2016 | Aug 22, 2016 | — | $0.02 | — | — |
Latest News
Frequently Asked Questions about TRSBF
What is TRSBF's current stock price?
What is the analyst price target for TRSBF?
What sector is 3SBio Inc. in?
What is TRSBF's market cap?
Does TRSBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TRSBF for comparison